Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review

Linda van der Tol,1 Marije L Sminia,2,3 Carla E M Hollak,1 Marieke Biegstraaten1

ABSTRACT
Background Screening for Fabry disease (FD) increasingly reveals individuals without characteristic features and with a variant of unknown significance in the α-galactosidase A (GLA) gene. Cornea verticillata (CV) assessment, as a characteristic sign of FD, may be a valuable diagnostic tool to assess whether these individuals have a non-classical phenotype or no FD at all.

Methods We performed a systematic review to estimate the prevalence of CV in FD. Additionally, CV prevalence was assessed in the Dutch FD cohort. Data were stratified by gender and phenotype (classical, non-classical, uncertain, no-FD) using predefined criteria.

Results CV was assessed in 21 cohorts (n=753, 330 men, age 0–85 years). Pooled prevalence was 69% (74% men, 66% women). In six studies, 77 (19 men) individuals with a non-classical or uncertain diagnosis were identified. Individual data were available in 4/6 studies (n=66, 16 men). CV was present in 24% (n=16, 2 men). 101 (35 men) subjects from the Dutch cohort were grouped as classical, of whom 86% (94% men, 82% women including five women who used amiodarone) had CV. Of the 25 (11 men) non-classical patients, 4 (three men) had CV. Subjects in the uncertain and no-FD groups did not have CV.

Conclusions CV is related to classical or biopsy-proven non-classical FD, with a very high sensitivity in classical men. Thus, presence of CV in an individual with an uncertain diagnosis of FD indicates a pathogenic GLA variant, in the absence of medication that may induce CV; if CV is absent, FD cannot be excluded.

INTRODUCTION
The lysosomal storage disorder Fabry disease (FD) is caused by variants in the X-chromosomal α-galactosidase A (GLA) gene.1 Due to impaired function of the lysosomal hydrolase α-galactosidase A (αGalA), globotriaosylceramide (Gb3) accumulates. Absent or near absent enzyme activity in men usually leads to classical FD, which is characterised by neuropathic pain with childhood onset, angiokeratoma and cornea verticillata (CV). End organ complications of the heart, kidney and brain arise later in life. Due to the X-linked nature of the disease, women are usually less severely affected.

Screening for FD and individual case finding has resulted in the identification of an increasing number of individuals with a GLA variant. While the birth prevalence of FD was previously estimated to be between 1:40 000 and 170 000,1,2 screening studies in high-risk populations (ie, groups with heart, kidney or brain disease) reveal a much higher prevalence of up to >1%. These individuals have a non-specific sign such as left ventricular hypertrophy or chronic kidney disease that may be attributable to FD, but most do not have the characteristic clinical and biochemical features of FD that are required to confirm a definite diagnosis of FD.4 Thus, the majority of these individuals have an uncertain diagnosis of FD in the presence of a genetic variant of unknown significance in the GLA gene.4 They may have a non-classical FD phenotype, or a neutral, non-disease-causing GLA variant.

Diagnostic tools are needed to confirm the presence of FD, but also to avoid unjustified labelling of individuals with a non-disease-causing GLA variant and wrongful initiation of costly treatment.

CV assessment may be a useful, non-invasive tool in the diagnosis of FD, specifically for those with an uncertain diagnosis of FD, since it has a high prevalence among patients with FD. The whorl-like pattern of corneal opacities is specific for FD,5 with the exception of some medications that may induce a corneal whorling that cannot be distinguished from that in FD (among others, amiodarone and chloroquine; for review, see Hollander and Aldave6). With this study we aim to value the presence of CV in the diagnosis of FD by investigating the prevalence of CV in individuals with a classical or non-classical FD phenotype and in individuals with an uncertain diagnosis of FD or no FD.

METHODS
Systematic review
Search
MEDLINE and EMBASE (1980 till January 2013) were searched for studies that assessed eye abnormalities in patients with FD. Search terms used were ‘Fabry disease’ combined with ‘Eye’, ‘Ophthalmology’, ‘Cornea verticillata’, ‘Tortuous retinal veins’, ‘Corneal opacity’ and their synonyms, Mesh terms (MEDLINE) and headings (EMBASE). In EMBASE, limits were used to exclude conference papers and abstracts.

First selection was done based on title and abstract. We selected full-text articles and reports with original data on eye abnormalities in subjects with FD in all languages (with an English abstract), including papers that presented data from international FD registries (Fabry Registry, Genzyme, a Sanofi company and Fabry Outcome Survey, FOS, Shire HGT). Case reports, newborn screening studies, comments, reviews and book chapters were excluded. Subsequently, studies were screened and included based on full text if the inclusion criteria were met.


Linda van der Tol,1 Marije L Sminia,2,3 Carla E M Hollak,1 Marieke Biegstraatten1

1Department of Endocrinology and Metabolism, Amsterdam Lysosome Center ’Sphinx’, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
2Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3Department of Ophthalmology, Medical Center Alkmaar, Alkmaar, The Netherlands

Correspondence to
Dr Marieke Biegstraatten, Academic Medical Center, Department of Internal Medicine, Room F5-166, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands; M. Biegstraatten@amc.uva.nl

Accepted 17 January 2015
Revised 11 January 2015
Received 20 November 2014
Published Online First
12 February 2015
**Data collection and analysis**

Data were recorded on the type of study (registry, screening or cohort study), participating study centre(s), number of subjects, gender and age groups (children and/or adults), together with the type of eye abnormalities assessed and therapy status at the time of ophthalmology assessment. A subanalysis was performed on subjects designated as non-classical or uncertain FD. For this purpose, subjects were selected who were reported to have

- a high residual enzyme activity;
- non-classical FD disease manifestations such as a cardiac or renal variant;
- a GLA variant that has frequently been associated with a non-classical FD phenotype;
- a GLA variant that is generally considered non-pathogenic/neural, or which pathogenicity is currently discussed in the literature (eg, p.R112H, p.P389A, p.N215S, p.A143T, c.936+919G>A (IVS4+919G>A)).

Raw prevalence data from all studies were combined for calculation of a weighed pooled prevalence, and specified for gender. Data from registry and screening studies were analysed separately.

**Dutch cohort**

**Patient selection and groups**

The Dutch database, comprising data from all subjects that visited the outpatient FD clinic with any GLA variant, was searched for all adults (>18 years of age). Data on the use of amiodarone and/or chloroquine at any time during the medical history were retrieved from the medical records.

Previously reported criteria were applied to classify subjects into four groups. Classical: the strict criteria for a definite diagnosis of FD were used to identify patients with a classical FD phenotype. Criteria include very low or absent enzyme activity in leucocytes (men), very high lysoGb3, FD-specific clinical characteristics (neuropathic pain, CV and angiokeratoma) and a family history that is positive for classical FD (see online supplementary table S1). For this study, an exception was made: CV was not used as a criterion to group subjects as classical because CV is the feature under investigation in this study. Non-classical: subjects who do not fulfil these detailed criteria for a definite diagnosis as described in online supplementary table S1 were grouped as non-classical if this subject or a family member has FD characteristic storage on electron microscopy in a biopsy of an affected organ (ie, heart or kidney). Uncertain: subjects who do not fulfil the strict criteria, and of whom a biopsy was not available, were grouped as uncertain. No FD: subjects were grouped as no FD (a neutral GLA variant) if a biopsy from a subject or from one of his/her family members did not show FD characteristic storage, or if the individual carried the well-known neutral variant p.D313Y. Subjects were excluded from the analyses if data were insufficient to apply the above criteria and/or CV assessment was missing.

Age at the time of the database search was calculated for all groups, and stratified by gender. For deceased subjects, age at death was used.

**CV assessments**

Assessment of CV was performed as part of regular clinical care at adulthood or adolescence. A slit-lamp examination was performed by an experienced ophthalmologist or trained physician (LT, supervised by ophthalmologist MS) to assess the left and right cornea. CV was recorded as present, mild or absent. Corneal photographs were obtained in some illustrative cases (see figure 2). Data on lenticular changes and retinal vessel tortuosity were not available.

**Data analyses**

Prevalence of CV was calculated for ‘classical’, ‘non-classical’, ‘uncertain’ and ‘no FD’ groups and specified for gender. The 95% CIs for proportions were calculated using the modified Wald method. Positive and negative predictive values were calculated for individuals who initially presented with an uncertain diagnosis of FD (non-classical and no FD, uncertain cases were excluded).

**RESULTS**

**Systematic review**

**Search**

In total, 460 records were retrieved from MEDLINE and EMBASE after duplicates were removed. Twenty-three studies were selected for data extraction. Two studies were subsequently added by the authors because of their interest for the research question: Whybra et al, not selected with the search, and Sher et al, initially excluded based on the publication date <1980. These studies included 21 cohort studies and 2 high-risk group screening studies and 2 registry studies. Details on selection and inclusion are presented in figure 1.

**Prevalence of CV**

CV was assessed in 753 individuals (330 men) from 21 cohorts with an age range of 0–85 years; for details, see table 1. Pooled prevalence of CV was 69% (range 26–96). Gender-specific data were available for 18 out of 21 studies (n=685, 295 men), revealing a pooled prevalence of 74% (range 14–94) for men and 66% (range 31–100) for women. Thirteen studies reported data on enzyme replacement therapy (ERT) administration, although in most cases the timing of CV assessment in relation to ERT administration was not specified. Therefore, further analysis of these data was not feasible.

In six cohort studies, 77 (19 men) individuals with a non-classical phenotype or uncertain FD could be identified (see table 2). Separate data for gender were available in four out of these six studies (n=66, 16 men). CV was present in 24% of non-classical or uncertain subjects (n=16, two men), mainly comprising the GLA variant c.936+919G>A (IVS4+919G>A) (n=15, one man) from one study on this specific GLA variant. Allen et al (and personal communication) reported mild CV in a 3.5-year-old boy with a p.A143T variant, while his brother with the same GLA variant did not have CV at age 1.5 years.

One of the registry studies reported a CV prevalence of 75% (men 73%, women 77%), while the second reported that in 11% of men and 12% of women CV was the presenting symptom. The high-risk group screening studies revealed that CV was absent in all adult individuals (n=29, 12 men) who were identified with a GLA variant.

**Dutch cohort**

**Patient selection and groups**

In total, 194 records of adults with a GLA variant were retrieved from the database, of whom 30 were excluded because data were not sufficient to fulfil the study criteria for disease groups and/or CV assessment was not (yet) performed due to lost to follow-up or because they had died before assessments were completed (n=45), or patients were recently referred and investigations were ongoing at the time of the study (n=5). In total,
144 subjects (56 men, 4 men deceased) were included in the analyses. Most subjects fit the criteria for a definite diagnosis of FD (classical, n=101, 35 men) and 25 subjects (11 men) were grouped as ‘non-classical’. FD was excluded in 7 subjects (no FD, five men), and in 11 subjects (five men) the diagnosis of FD was still uncertain.

One exception to the classification criteria was made. In three families (n=5 subjects), biopsies of an affected organ were lacking. Because other families in our cohort with the same GLA variant did have positive biopsies, these subjects were classified as non-classical, biopsy-proven disease.

CV prevalence and details
CV prevalence in the Dutch cohort is depicted in table 3. Nearly all men in the classical group had CV (94%). The two subjects without CV had received >9 years of treatment with ERT at the time of CV assessment. These two men had the p.D136Y and p.R342Q GLA variant causing complete absence of αGalA activity in leucocytes, very high lysoGb3 in plasma, acroparesthesia, white matter lesions and left ventricular hypertrophy. Eighty-two percent of women in the classical group had CV, of whom five women had used amiodarone for cardiac rhythm abnormalities before or at the time of CV assessment. See figure 2A for an example of characteristic CV.

Of the 25 non-classical subjects, 4 (16%, three men and one woman) had CV. One woman and two men had the p.P389A variant, and one man had the p.R112H variant. The clinical and biochemical characteristics of the subject and family members with the p.R112H variant are described in detail by Smid et al. The corneal changes in these patients were subtle and limited to one or two small subepithelial deposits, thereby differing from the typical whorl-like pattern that is seen in classical patients with FD (figure 2B). These subjects did not use medication that is associated with CV.

There were no false-positive cases (none of the subjects in the no-FD group had CV). For individuals who presented to our clinic with an uncertain diagnosis (groups non-classical and no-FD), the positive predictive value of CV is 1 and the negative predictive value is 0.25.

DISCUSSION
Screening for FD is often performed in high-risk groups, for example, among individuals with chronic kidney disease, left ventricular hypertrophy or stroke, which may be attributed to FD. If a genetic variant in the GLA gene is found, the diagnosis of FD can be uncertain since characteristic FD signs or symptoms are often lacking. CV assessment may be helpful in these cases. Our study revealed a high prevalence of 94% in classically affected men, and there were no false positives. In patients with FD with a classical phenotype, CV is usually diffuse with a typical whorl-like pattern. In patients with the non-classical phenotype, subtle changes were identified, which confirms previous findings of CV in individuals with a non-classical phenotype with the c.936+919G>A (IVS4+919G>A) variant. Our findings suggest that the presence of CV, in the absence of medication that may induce CV, confirms the diagnosis of classical or non-classical FD. The absence of CV, however, does not exclude FD. Especially in cases with a non-classical phenotype, CV may be absent, even if characteristic storage is present in an affected organ, such as the heart or kidney.

Figure 1  Selection of studies.

Figure 2  (A) Cornea verticillata (arrow) in a 45-year-old untreated woman with a classical Fabry disease (FD) phenotype. Arrow: origin of the pigmented verticillata. (B and C) Subtle cornea deposits (arrow) in a 36-year-old man with a non-classical FD phenotype.
The prevalence of CV among patients with FD in the literature is variable and generally lower in comparison to the Dutch cohort. This discrepancy is probably caused by the inclusion of subjects with a non-classical phenotype or even subjects with a neutral GLA variant in the reviewed studies. It was not possible to correct for this bias because the required clinical, biochemical and genetic details were most often not provided.

Additionally, age may have affected the prevalence of CV because of the inclusion of children in several studies. Borgwardt et al\(^\text{16}\) described two boys who started ERT treatment at the age of 10 and 12, in whom CV was absent at baseline, but who developed CV after 1 year of follow-up. These cases suggest that CV may not always be present from birth. Although in the above cases ERT did not seem to influence the development of CV, the effect of ERT on CV has not been studied systematically and may have influenced the data. In the Dutch cohort, two men did not have CV at adulthood, while clinical and biochemical evaluation as well as the family history demonstrated a classical FD phenotype. As previously suggested by Sodi et al\(^\text{35}\), we postulate that long-term ERT may have corrected the corneal changes in these subjects.

This study focused on CV and did not study other ocular changes that are related to FD. Posterior lens cataract has previously been described as a specific feature in FD.\(^\text{37}\) This type of cases suggest that CV may not always be present from birth.

### Table 1. Cornea verticillata (CV) prevalence in reviewed studies

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Centre</th>
<th>Patients n (m/f)</th>
<th>CV prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen*</td>
<td>2010</td>
<td>UK (Cambridge)</td>
<td>26 (12/14)</td>
<td>50</td>
</tr>
<tr>
<td>Barba Romero</td>
<td>2004</td>
<td>Spain</td>
<td>14 (1/0)</td>
<td>36</td>
</tr>
<tr>
<td>Beltran-Becerra</td>
<td>2012</td>
<td>Mexico</td>
<td>13 (7/6)</td>
<td>46</td>
</tr>
<tr>
<td>Borgwardt</td>
<td>2012</td>
<td>Denmark</td>
<td>10 (6/4)</td>
<td>90</td>
</tr>
<tr>
<td>Choi</td>
<td>2008</td>
<td>Korea</td>
<td>11 (8/3)</td>
<td>82</td>
</tr>
<tr>
<td>Falke</td>
<td>2009</td>
<td>Germany (Rostock)</td>
<td>22 (6/16)</td>
<td>46</td>
</tr>
<tr>
<td>Gupta*</td>
<td>2005</td>
<td>USA (Maryland)</td>
<td>57 (0/57)</td>
<td>82</td>
</tr>
<tr>
<td>Kaminsky</td>
<td>2013</td>
<td>France (Nancy)</td>
<td>108 (41/67)</td>
<td>54</td>
</tr>
<tr>
<td>Kobayashi</td>
<td>2008</td>
<td>Japan</td>
<td>36 (0/36)</td>
<td>50</td>
</tr>
<tr>
<td>Lin*</td>
<td>2010</td>
<td>Taiwan</td>
<td>52 (7/45)</td>
<td>29</td>
</tr>
<tr>
<td>Nguyen</td>
<td>2005</td>
<td>Australia</td>
<td>66 (34/32)</td>
<td>83</td>
</tr>
<tr>
<td>Orsaud</td>
<td>2003</td>
<td>France (Paris)</td>
<td>32 (3/20)</td>
<td>56</td>
</tr>
<tr>
<td>Pitz</td>
<td>2009</td>
<td>Germany (Mainz)</td>
<td>31 (15/16)</td>
<td>81</td>
</tr>
<tr>
<td>Rákóczi*</td>
<td>2007</td>
<td>Hungary</td>
<td>31 (15/16)</td>
<td>65</td>
</tr>
<tr>
<td>Reisin</td>
<td>2010</td>
<td>Argentina</td>
<td>54 (31/23)</td>
<td>96</td>
</tr>
<tr>
<td>Ries*</td>
<td>2003</td>
<td>Germany (Mainz), Italy,</td>
<td>33 (15/18)</td>
<td>76</td>
</tr>
<tr>
<td>Ries*</td>
<td>2005</td>
<td>USA (Maryland)</td>
<td>24 (24/0)</td>
<td>88</td>
</tr>
<tr>
<td>Sher</td>
<td>1979</td>
<td>USA (Minnesota)</td>
<td>62 (37/25)</td>
<td>92</td>
</tr>
<tr>
<td>Sodi</td>
<td>2013</td>
<td>Italy (Florence), Belgium (Charleroi), UK (London), Germany (Mainz)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tøndel</td>
<td>2008</td>
<td>Norway</td>
<td>16 (9/7)</td>
<td>94</td>
</tr>
<tr>
<td>Whybra</td>
<td>2001</td>
<td>Germany (Mainz)</td>
<td>20 (0/20)</td>
<td>70</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>753 (330/423)</td>
<td>69</td>
</tr>
</tbody>
</table>

*Non-classical or uncertain cases were reported; see table 2 for details.
†Only studies that reported gender-specific data were used for male and female prevalence.
–, not applicable or missing data; m/f, male/female.

### Table 2. CV prevalence in non-classical/uncertain cases in the literature

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>n (m/f)</th>
<th>GLA variant</th>
<th>CV prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gupta</td>
<td>2005</td>
<td>7 (0/7)</td>
<td>4x p.R112H, 3x p.N215S</td>
<td>–/14/1 0/0</td>
</tr>
<tr>
<td>Lin</td>
<td>2010</td>
<td>52 (7/45)</td>
<td>c.936+919G&gt;A (IVS4+919G&gt;A)</td>
<td>29/15/1 0/0</td>
</tr>
<tr>
<td>Ries</td>
<td>2003</td>
<td>2 (2/0)</td>
<td>p.A143T</td>
<td>0/0/0 –/–</td>
</tr>
<tr>
<td>Ries</td>
<td>2005</td>
<td>3 (3/0)</td>
<td>2x p.R112H, 1x p.A97V</td>
<td>0/0/0 –/–</td>
</tr>
</tbody>
</table>

–, not applicable or missing data; CV, cornea verticillata; m/f, male/female.
cataract has been reported in a few studies only with a prevalence up to 53% of men with FD.12 24 30 35

Another FD-associated ocular feature is retinal vascular tortuosity. This feature has not often been reported in the literature. Importantly, and in analogy with tortuosity and dilatation of the cerebral basilar artery,38 39 the specificity is yet uncertain as tortuous and dilated retinal vessels are reported to be present in other diseases that affect the vasculature such as diabetes and may be subjected to age.40 Because our study was observational and cataract and retinal vessels are not assessed routinely, these data were not available for the Dutch cohort.

In addition, we did not strive to study the nature of FD-related ocular changes, but we pursued to assess the diagnostic applicability of an assessment that is non-invasive and worldwide applicable in order to discern patients with a classical and non-classical FD phenotype from those without FD. We are confident that CV assessment, as the current most extensively studied and understood ocular feature in FD and with the highest prevalence, is the best suitable ophthalmological assessment to use for diagnostic purposes.

Data from the Dutch cohort show a correlation between CV and a classical FD phenotype or biopsy-proven non-classical FD. But the number of subjects who were classified as ‘no FD’ in this cohort is small. Further studies are needed to confirm that CV is not present in subjects with a neutral GLA variant (no FD), and thus, that the presence of CV predicts a classical or non-classical FD phenotype. We are confident, however, that the presence of diffuse CV with a whorl-like pattern can substitute the gold standard for FD (a biopsy of an affected organ) in patients with an uncertain diagnosis of FD. Whether this also applies to the more subtle changes that are usually seen in non-classical patients with FD should be subject of further studies.

In conclusion, in individuals with an uncertain diagnosis of FD, when no medication is used that can cause CV, the presence of CV provides evidence for FD.

Acknowledgements We thank Frouke Kingma, medical student at the University of Amsterdam, for her contribution to the literature study. Dick de Vries is acknowledged for his assistance with the cornea photography.

Contributors LvDT: study design, data acquisition, data analyses, data interpretation and first draft of manuscript. MLS: data acquisition and supervision, data interpretation and revision of manuscript. MB and CEH: study design, data interpretation and revision of manuscript.

Funding This study was performed within the framework of the Dutch Top Institute Pharma (TIPharma, project number T6-504: ‘Fabry or not Fabry: valorization of clinical and laboratory tools for improved diagnosis of Fabry disease’. TIPharma is a non-profit organisation that catalyses research by founding partnerships between academia and industry. Partners: Genzyme, a Sanofi company; Academic Medical Center, University of Amsterdam; Subsidising Party: Shire HTG. http://www.tipharma.com/ pharmaceutical-research-projects/drug-discovery-development-and-utilisation/hamat-study.html. The industry partners had no role in the content of this manuscript.

Competing interests LvdT has received travel support and reimbursement of expenses from Actelion, Shire HTG or Genzyme. MB and CEH have received travel support, honoraria for consultancies and educational grants from Actelion, Genzyme, Shire HTG, Protalix or Amicus. All financial arrangements are made with the AMC Medical research BV in accordance with the AMC Research Code. MLS reader of retinal images in FIELD study, a randomised controlled trial, Genzyme.

Ethics approval Institutional review board/ethics committee ruled that approval was not required for this study.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


